Scott M Schuetze, Karla V Ballman, Rachel Heise, Kristen N Ganjoo, Elizabeth J Davis, Suzanne George, Melissa A Burgess, Edwin Choy, Dale R Shepard, Gabriel Tinoco, Angela Hirbe, Ciara M Kelly, Steven Attia, Hari A Deshpande, Gary K Schwartz, Brittany L Siontis, Richard F Riedel, Margaret von Mehren, Erin Kozlowski, Helen X Chen, Caroline Astbury, Brian P Rubin
PURPOSE: Epithelioid hemangioendothelioma (EHE) is a rare vascular cancer with pathogenic TAZ-CAMTA1 operating as an oncogenic driver through activation of MAPK pathway. Trametinib is an inhibitor of MEK, a critical kinase in the MAPK pathway. We sought to evaluate the effect of trametinib in patients with EHE. PATIENTS AND METHODS: A phase 2 trial of trametinib was conducted in patients with locally advanced or metastatic EHE. Eligibility requirements included evidence of tumor progression or presence of EHE-related pain requiring opiates for management prior to enrollment...
March 6, 2024: Clinical Cancer Research